Clinical Trial Update: Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy [Phase 2, Phase 3]

View source ↗

Summary

This update reports the efficacy and safety outcomes of oral nilotinib (AMN107) in adults with chronic myeloid leukemia resistant or intolerant to imatinib mesy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Leukemia, Myeloid, Chronic | Phase 2, Phase 3 | Status: COMPLETED